Acorn Capital Advisors
$366M 13F equity value
23 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Acorn Capital Advisors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| CGON | CG ONCOLOGY INC | 1,131,500 | $80M | 21.9% |
| URGN | UROGEN PHARMA LTD | 1,673,420 | $62M | 16.8% |
| TRVI | TREVI THERAPEUTICS INC | 2,144,844 | $40M | 10.9% |
| CADL | CANDEL THERAPEUTICS INC | 3,497,948 | $36M | 9.8% |
| PBYI | PUMA BIOTECHNOLOGY INC | 4,131,299 | $34M | 9.1% |
| JBIO | JADE BIOSCEINCES INC | 986,760 | $22M | 6.0% |
| BCAX | BICARA THERAPEUTICS | 643,381 | $19M | 5.2% |
| KPTI | KARYOPHARM THERAPEUTICS INC | 1,518,113 | $15M | 4.0% |
| OKUR | ONKURE THERAPEUTICS INC | 2,839,674 | $13M | 3.5% |
| HELP | HELUS PHARMA INC. | 1,540,266 | $10M | 2.8% |
Track Acorn Capital Advisors's 13F portfolio: $366M in reported holdings, 23 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}